Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Shares Outstanding (Diluted Average) (2016 - 2025)

Zevra Therapeutics' Shares Outstanding (Diluted Average) history spans 8 years, with the latest figure at $57.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 23.81% year-over-year to $57.3 million; the TTM value through Dec 2025 reached $57.3 million, up 23.81%, while the annual FY2025 figure was $57.3 million, 23.81% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $57.3 million in Q4 2025 per ZVRA's latest filing, up from $56.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $57.3 million in Q4 2025 to a low of $27.9 million in Q3 2021.
  • Average Shares Outstanding (Diluted Average) over 3 years is $43.2 million, with a median of $43.8 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Diluted Average): surged 739.3% in 2021, then grew 23.81% in 2025.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $29.8 million in 2021, then soared by 55.38% to $46.3 million in 2024, then grew by 23.81% to $57.3 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Shares Outstanding (Diluted Average) are $57.3 million (Q4 2025), $56.8 million (Q3 2025), and $56.1 million (Q2 2025).